Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-05-05 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Rett Syndrome Phase I/II trial shows significant benefits 8 pages 624.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 6 May 2024 reporting detailed clinical trial results for Neurotech's Phase I/II Rett Syndrome clinical trial. It includes comprehensive data on primary and secondary endpoints, safety results, and patient characteristics. The content is focused on clinical efficacy and safety outcomes rather than financial performance or regulatory compliance. It is not a full annual or interim financial report, nor is it a call transcript or management change announcement. The document is a detailed clinical trial results announcement, which typically falls under regulatory filings or announcements related to clinical progress. Given the detailed nature and the context of an ASX announcement, it is best classified as a Regulatory Filing (RNS) because it does not fit the other financial or governance categories and is a formal regulatory announcement of clinical trial results.
2024-05-05 English
Investor Presentation 27 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated 6 May 2024 by Neurotech International Limited, focusing on clinical trial results for Rett Syndrome. It includes trial design, patient characteristics, safety data, efficacy measures, and other clinical information. The text explicitly states it is a presentation prepared for general information and not an investment offer or prospectus. It contains no financial statements or regulatory filings but rather clinical trial data and company strategy. The content and format align with an Investor Presentation (IP) rather than an Annual Report, Earnings Release, or Regulatory Filing. The length (15,000 characters) and detailed clinical data support this classification as a presentation rather than a brief announcement or report publication notice.
2024-05-05 English
Investor Webinar on Rett Syndrome Clinical Trial Results 1
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 6 May 2024 about an upcoming investor webinar to discuss Phase I/II clinical trial results for Rett Syndrome. It invites shareholders and investors to register for the webinar and mentions that a recording will be available afterward. The document does not contain any financial statements, detailed financial data, or comprehensive report content. It is essentially an announcement of an event (investor presentation) rather than the presentation or report itself. Given the nature of the content, it fits best as an Investor Presentation (IP) announcement, but since it is primarily an announcement of the webinar event and not the presentation material itself, it aligns with the Investor Presentation category. The document length is short and does not contain detailed financial or operational data, so it is not an Annual Report, Interim Report, or Earnings Release. Therefore, the classification is Investor Presentation (IP) with high confidence.
2024-05-05 English
Trading Halt 2 pages 147.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited requesting a trading halt on its securities pending the release of an announcement about clinical trial results. It is a short notice related to trading status and does not contain financial data, management discussion, or detailed report content. It is not a report itself but an announcement related to trading status. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-05-02 English
Application for quotation of securities - NTI 6 pages 18.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement by Neurotech International Limited regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references previous announcements (Appendix 3B and 3G) related to the securities issuance. The content focuses on the listing and quotation of shares rather than financial results, management changes, or other report types. This matches the category of Share Issue/Capital Change filings, which cover announcements about new share issues and capital changes. The document length is about 5707 characters, and it is a full announcement, not just a brief note or a report publication announcement. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2024-04-23 English
Secondary Trading Notice 1 page 93.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 24 April 2024. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2752 characters) and is a regulatory notice about share issuance without a full disclosure document. It does not contain financial statements, detailed financial data, or management discussion. It is not a full report but a regulatory announcement related to capital raising/shares issued without disclosure. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes. It is not a report publication announcement or regulatory filing fallback because it provides substantive information about the share issuance event itself.
2024-04-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.